Eesti - eesti - Ravimiamet

intervet international b.v. - proligestoon - süstesuspensioon - 100mg 1ml 20ml 1tk

Eesti - eesti - Ravimiamet

virbac - gentamütsiin - silmatilgad, lahus - 3000rÜ 1ml 5ml 1tk

Eesti - eesti - Ravimiamet

intervet international b.v. - proligestoon - süstelahus - 100mg 1ml 20ml 1tk

Eesti - eesti - Ravimiamet

intervet international b.v. - lindude nakkava bronhiidi viirusvaktsiin+newcastle'i tõve viirus-/paramüksoviirusvaktsiin - lüofilisaat okulonasaalsuspensiooni valmistamiseks/joogivees manustamiseks - 1000eid50+1000000eld50 1annus 2500annus 10tk

Eesti - eesti - Ravimiamet

intervet international b.v. - lindude nakkava bronhiidi viirusvaktsiin - lüofilisaat okulonasaalsuspensiooni valmistamiseks/joogivees manustamiseks - 3log10 eid50 1annus 2500annus 10tk; 3log10 eid50 1annus 2500annus 12tk; 3log10 eid50 1annus 10000annus 10tk; 3log10 eid50 1annus 5000annus 10tk; 3log10 eid50 1annus 10000annus 12tk; 3log10 eid50 1annus 5000annus 12tk; 3log10 eid50 1annus 1000annus 10tk; 3log10 eid50 1annus 1000annus 12tk

Eesti - eesti - Ravimiamet

g. pohl-boskamp gmbh & co. kg - eukalüpti, magusa apelsini, mürdi ja sidruni rektifitseeritud eeterlike õlide destillaat - gastroresistentne pehmekapsel - 120mg 20tk

Eesti - eesti - Ravimiamet

g. pohl-boskamp gmbh & co. kg - eukalüpti, magusa apelsini, mürdi ja sidruni rektifitseeritud eeterlike õlide destillaat - gastroresistentne pehmekapsel - 300mg 50tk; 300mg 20tk; 300mg 100tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

vmd n.v. - tulatromütsiin - antibacterials for systemic use, macrolides - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. the product should only be used if pigs are expected to develop the disease within 2–3 days. lambad: nakkusliku pododermatiidi (suu mädanemine) varajase staadiumi ravi, mis on seotud virulentse dichelobacter nodosus'ega ja vajab süsteemset ravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

biogen netherlands b.v. - natalisumab - hulgiskleroos - selektiivsed immunosupressandid - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sandoz gmbh - natalisumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ja 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.